Fabry Disease Clinical Trial
Official title:
An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase Beta-Treated Fabry Disease Patients With GLA IVS4 919 G>A Mutation in Taiwan
This is a national, multicenter, observational, cohort study designed to assess clinical outcomes upon agalsidase beta treatment, to characterize the clinical manifestations, and to collect the natural history on male and female Fabry disease adult patients who carry the GLA IVS4. This study aims to retrospectively and prospectively investigate the disease natural history, clinical manifestations, and the treatment outcomes upon agalsidase beta in Fabry disease (FD) patients carrying the GLA IVS4 mutation from medical records, physician assessments, and patient-reported outcomes.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | September 4, 2026 |
Est. primary completion date | September 4, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provide signed informed consent. Cohort 1: - Male or female Fabry disease patient with documented GLA IVS4 in medical record. - Age = 18 years old at the time of signing informed consent. - The maximum proportion of female is 20% of cohort 1. - Patient who has received agalsidase beta treatment for at least 6 months. - The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months prior to agalsidase beta treatment initiation. Cohort 2: - Male or female Fabry disease patient with documented GLA IVS4 in medical record. - Age = 18 years old at the time of signing informed consent. - The maximum proportion of female is 20% of cohort 2. - Patient who plans to apply for the National Health Insurance Reimbursement for agalsidase beta medication. - The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months prior to agalsidase beta treatment initiation. Cohort 3: - Male or female Fabry disease patients with documented GLA IVS4 mutation in medical record. - Male patient is aged = 30 years old and female patient is aged = 40 years old at the time of signing informed consent. - The maximum proportion of female is 20% of cohort 3. - Patient who has never received agalsidase alpha or agalsidase beta treatment (ERT-naïve). - Elevated blood lyso-Gb3. - At least ONE of the following conditions documented in medical record: 1. cardiac parameter abnormalities (e.g. via imaging, electrophysiology, or biomarker); 2. at least one FD-related sign/symptom. - The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months. - Patients who are expected not to receive ERT or FD-specific treatment per investigator's judgement. Exclusion Criteria: - Any condition that, in the opinion of the Investigator, may interfere with patient's participation in the study, such as life expectancy of less than 6 months (e.g. diagnosed with malignancy, CAD) - Fabry patients who have severe heart disease (NYHA Class IV) or severe myocardial fibrosis per investigator judgement - Known non-Fabry disease infiltrative cardiomyopathy including amyloidosis - Known non-GLA genetic (e.g., sarcomeric, metabolic mutations) hypertrophic cardiomyopathy. - Patients who are receiving any Fabry disease-specific treatment (enzyme replacement therapy, chaperone therapy, substrate reduction therapy, or gene therapy) other than agalsidase beta for Fabry disease - Pregnancy or suspected pregnancy - Patient diagnosed with moderate to severe dementia - Unstable patient condition as judged by investigator (e.g., hypertension, diabetes, and systematic disease) |
Country | Name | City | State |
---|---|---|---|
Taiwan | Investigational Site Number :1580004 | Taichung | |
Taiwan | Investigational Site Number :1580005 | Tainan | |
Taiwan | Investigational Site Number :1580001 | Taipei | |
Taiwan | Investigational Site Number :1580002 | Taipei | |
Taiwan | Investigational Site Number :1580003 | Taipei |
Lead Sponsor | Collaborator |
---|---|
Sanofi |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cohort 1: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients | through study completion with a minimum of 2 years | ||
Primary | Cohort 2: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients | up to 1.5 years | ||
Secondary | Change of Left posterior wall thickness (LPWT) as measured by echocardiography | For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years | ||
Secondary | Change of Interventricular septal thickness (IVST) as measured by echocardiography | For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years | ||
Secondary | Change of blood Globotriaosylsphingosine (lyso-Gb3) concentration | For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years | ||
Secondary | Change of left ventricular mass index (LVMI) as measured by echocardiography in ERT-naive patients | For cohort 3, through study completion with a minimum of 1.5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04893889 -
Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease.
|
N/A | |
Completed |
NCT04455230 -
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
|
Phase 1/Phase 2 | |
Completed |
NCT01218659 -
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
|
Phase 3 | |
Completed |
NCT00304512 -
A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease
|
Phase 2 | |
Withdrawn |
NCT04189601 -
Complement Activation in the Lysosomal Storage Disorders
|
||
Completed |
NCT03500094 -
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
|
Phase 3 | |
Withdrawn |
NCT04143958 -
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
|
Phase 4 | |
Recruiting |
NCT02994303 -
Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy
|
N/A | |
Completed |
NCT01947634 -
Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.
|
N/A | |
Recruiting |
NCT01695161 -
Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.
|
N/A | |
Completed |
NCT01853852 -
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
|
Phase 1 | |
Completed |
NCT00701415 -
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
|
Phase 3 | |
Completed |
NCT00068107 -
Dosing Study of Replagal in Patients With Fabry Disease
|
Phase 2 | |
Completed |
NCT01997489 -
Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
|
Phase 4 | |
Recruiting |
NCT06007768 -
Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
|
||
Recruiting |
NCT05698901 -
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
|
||
Active, not recruiting |
NCT03305250 -
Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease
|
N/A | |
Terminated |
NCT00526071 -
Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
|
Phase 2 | |
Active, not recruiting |
NCT03566017 -
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
|
Phase 3 | |
Recruiting |
NCT06065605 -
Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease
|